Search research articles
Contact Us
Filters
Showing results (211-220 of 499) with videos related to
Page
of 50
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 18, 2013
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer
Marc Peeters, Kelly S Oliner, Alex Parker, et al.
Angiogenesis
|
July 12, 2014
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
Sanne de Haas, Paul Delmar, Aruna T Bansal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2023
Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Rafael G Amado, Michael Wolf, Marc Peeters, et al.
Future Oncology (London, England)
|
July 2, 2024
Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer
Gerald W Prager, Julien Taieb, Marwan Fakih, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 25, 2017
Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona
Alexander Baraniskin, Jean-Luc Van Laethem, Lucjan Wyrwicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2007
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem, Marc Peeters, Salvatore Siena, et al.
Angiogenesis
|
February 22, 2014
Genetic markers of bevacizumab-induced hypertension
Diether Lambrechts, Matthieu Moisse, Paul Delmar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 5, 2008
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G Amado, Michael Wolf, Marc Peeters, et al.
Future Oncology (London, England)
|
December 26, 2024
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer
John H Strickler, Tanios Bekaii-Saab, Andrea Cercek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2013
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database
Nadine J McCleary, Jeffrey A Meyerhardt, Erin Green, et al.
Page
of 50
Search research articles
Search
Showing results (211-220 of 499) with videos related to
Sort By:
Page
of 50
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 18, 2013
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer
Marc Peeters, Kelly S Oliner, Alex Parker, et al.
Angiogenesis
|
July 12, 2014
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
Sanne de Haas, Paul Delmar, Aruna T Bansal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2023
Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Rafael G Amado, Michael Wolf, Marc Peeters, et al.
Future Oncology (London, England)
|
July 2, 2024
Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer
Gerald W Prager, Julien Taieb, Marwan Fakih, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 25, 2017
Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona
Alexander Baraniskin, Jean-Luc Van Laethem, Lucjan Wyrwicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2007
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem, Marc Peeters, Salvatore Siena, et al.
Angiogenesis
|
February 22, 2014
Genetic markers of bevacizumab-induced hypertension
Diether Lambrechts, Matthieu Moisse, Paul Delmar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 5, 2008
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G Amado, Michael Wolf, Marc Peeters, et al.
Future Oncology (London, England)
|
December 26, 2024
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer
John H Strickler, Tanios Bekaii-Saab, Andrea Cercek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2013
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database
Nadine J McCleary, Jeffrey A Meyerhardt, Erin Green, et al.
Page
of 50